Why the study?
Early neurological deterioration after intravenous thrombolysis increases mortality and morbidity in acute ischemic stroke, motivating investigation into whether serum Cav-1 and NGB levels predict its occurrence and poor prognosis.
Do serum Cav-1 and NGB levels predict early neurological deterioration and poor prognosis after intravenous thrombolysis in patients with acute ischemic stroke?
Do serum Cav-1 and NGB levels predict early neurological deterioration and poor prognosis after intravenous thrombolysis in patients with acute ischemic stroke?
Serum Cav-1 and NGB levels measured before intravenous thrombolysis may serve as predictive biomarkers for early neurological deterioration and poor 3-month prognosis in acute ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Serum Cav-1 and NGB may predict END after IAT in AIS; leaves open clinical utility pending prospective validation.
Zhang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: